GH-Axis · Research Compound
Tesamorelin
A growth-hormone-releasing hormone (GHRH) analog studied in growth-hormone-axis and visceral-fat (belly-fat) research.
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), consisting of the 44-amino-acid human GHRH sequence with a stabilizing modification. It is studied for its ability to stimulate the body’s own growth-hormone production rather than introducing exogenous hormone, and has the distinction of an approved clinical indication (HIV-associated lipodystrophy) in addition to broader research interest.
In the research-compound space, Tesamorelin appears frequently in growth-hormone-axis mechanism research. Material here is provided for research-use-only, educational purposes.
Research areas
GHRH-Analog Mechanism
Stimulates pituitary release of endogenous growth hormone, studied as a physiologic alternative to direct GH administration.
Clinical Research Context
Holds an approved clinical indication (HIV-associated lipodystrophy); trial literature characterizes its effects on adipose tissue.
GH-Axis & IGF-1
Research examines downstream IGF-1 signaling and growth-hormone pulse dynamics.
Mechanism Studies
Studied for its GHRH-receptor activity and growth-hormone-axis effects.
Recent research findings
- 2024Continued growth-hormone-axis research on GHRH-analog pharmacology and IGF-1 signaling.
- 2023Reviews summarized the clinical evidence base from approved-indication trials.
- 2010Falutz et al. published pivotal trial data from the approved clinical indication.
Published Research & Citations
The research summarized above is drawn from published, peer-reviewed studies. Explore the 6 sources below — links open the abstract or, where marked, the full free article on the U.S. National Library of Medicine (PubMed / PMC).
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. New England Journal of Medicine, 2007. Pivotal randomized trial showing tesamorelin selectively reduced visceral fat in HIV-associated lipodystrophy.
- Falutz J, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials. Journal of Clinical Endocrinology & Metabolism, 2010. Pooled phase-3 data confirming visceral-fat reduction and safety profile.
- Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 2012. Links visceral-fat reduction to improvements in metabolic markers.
- Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV, 2019. Free full text Open-access randomized trial reporting reduced liver fat with tesamorelin.
- Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs, 2011. Review of tesamorelin's pharmacology, efficacy, and tolerability.
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 2024. Recent trial evaluating tesamorelin in contemporary antiretroviral regimens.